China International Capital Corporation Limited(601995)
About nuocheng Jianhua Pharmaceutical Co., Ltd
（InnoCare Pharma Limited）
Listing recommendation for initial public offering of RMB common shares (A shares) and listing on the science and Innovation Board
Sponsor
(27th and 28th floors, building 2, international trade building, No. 1 Jianguomenwai street, Chaoyang District, Beijing) April, 2002
Statement
China International Capital Corporation Limited(601995) (hereinafter referred to as “the sponsor”, “the sponsor” or ” China International Capital Corporation Limited(601995) “) and its sponsor representative have been in accordance with the company law of the people’s Republic of China (hereinafter referred to as “the company law”) The securities law of the people’s Republic of China (hereinafter referred to as the “Securities Law”) and other laws and regulations, as well as the relevant provisions of the China Securities Regulatory Commission (hereinafter referred to as the “CSRC”) and the Shanghai Stock Exchange (hereinafter referred to as the “Shanghai Stock Exchange”), are honest, trustworthy, diligent and responsible, issue the listing recommendation letter in strict accordance with the business rules and industry self-discipline norms formulated according to law, and ensure that the documents issued are true, accurate and reliable Complete.
Unless otherwise specified, the relevant terms in this listing recommendation letter have the same meaning as in the prospectus of innocare Pharma Limited’s initial public offering of RMB common shares (A shares) and listing on the science and Innovation Board (the draft of the meeting).
catalogue
Declare that one
1、 Issuer profile three
2、 Issuance of shares applying for listing forty-one
3、 Sponsor representatives, CO sponsors and other members of the project team for this securities issuance and listing forty-two
4、 Description of whether the recommendation institution has any circumstances that may affect its fair performance of recommendation duties forty-three
5、 Commitments of the sponsor forty-three
6、 The decision-making procedures performed by the Issuer on this securities issuance and listing forty-four
7、 Verification opinions of the recommendation institution on the issuer’s compliance with the positioning requirements of the science and Innovation Board forty-seven
8、 The sponsor’s explanation on whether the issuer meets the listing conditions of the science and Innovation Board forty-nine
9、 The arrangement of the recommendation institution for the continuous supervision of the issuer fifty
10、 The contact address, telephone number and other means of communication of the recommendation institution and relevant recommendation representatives fifty-one
11、 Other matters that the recommendation institution believes should be explained fifty-one
12、 The recommendation conclusion of the sponsor on this stock listing 52 I. overview of the issuer (I) basic information of the issuer
(I) basic information of the issuer
English name innocare Pharma Limited Chinese Name: nuocheng Jianhua Pharmaceutical Co., Ltd
Total authorized share capital: USD 50000 date of establishment: November 3, 2015
Jisong Cui (Cui Jisong), Renbin Zhao have 25000000000 legal shares in total. Directors of the company (Zhao Renbin), Shi Yigong, Fu Shan, Jin Ming, Xie Ronggang, Zemin Jason Zhang (Zhang Zemin), Hu Lan and Chen Kaixian
1499673235 shares (up to December 31, 2021 of Ogier global (Cayman) Limited, 89 total issued shares) registered address: Nexus way, camana Bay, grand
Cayman, KY1-9009, Cayman Islands
The controlling shareholder has no principal place of business in China, building 8, courtyard 8, shengshengyuan Road, Beijing Centergate Technologies (Holding) Co.Ltd(000931) Life Science Park, Changping District, Beijing
The actual controller is not in other trading places (application)
Please) listing or listing 09969 (Hong Kong Stock Exchange)
The industry classification is in accordance with the industry catalogue and classification principles of the guidelines for Industry Classification of listed companies (revised in 2012) issued by the CSRC. The industry of the company is “pharmaceutical manufacturing industry (C27)”
(II) intermediaries related to this issue
Sponsor (lead underwriter) China International Capital Corporation Limited(601995)
Lawyer of the issuer: Shanghai Fangda law firm audit institution: Ernst & Young Huaming Certified Public Accountants (special general partnership)
Sponsor (lead underwriter) sponsor of Beijing Jiayuan law firm (lead underwriter of Tianjian Certified Public Accountants (special general partner)
(II) main financial data and indicators
During the reporting period, the main financial data (audited by Ernst & Young) and financial indicators of the issuer’s consolidated financial statements are as follows:
Project 2021 / 2020 / 2019/
December 31, 2021 December 31, 2020 December 31, 2019 December 31
Total assets (10000 yuan) 741496994541056626420418
Owner’s equity attributable to the parent company 5604559531040133 – Sinoseal Holding Co.Ltd(300470) 9400 yuan
Asset liability ratio (consolidated) (%) 23.68 30.40 211.57
Operating income (10000 yuan) 10430328 136.36 124.70
Net profit (10000 yuan) -666790 -3918654 -21503513
The net profit (10000 yuan) attributable to the owner of the parent company is -645460 -3913951 -21413878 after deducting non recurring profits and losses
Net profit from owners of the parent company -536602 -2746732 -233919700 yuan
Project 2021 / 2020 / 2019/
December 31, 2021 December 31, 2020 December 31, 2019 December 31
Basic earnings per share (yuan) -0.05 -0.40 -9.32
Diluted earnings per share (yuan) -0.05 -0.40 -9.32
Weighted average return on net assets -1.24 -23.35 109.47 (%)
Net cash flow from / (used in) operating activities of 1670583 -2976185 -204647 yuan (10000 yuan)
Cash dividend (10000 yuan) —
Proportion of R & D investment in operating income 70.2531042861877872 (%) (III) main business operation
Nuocheng Jianhua is an innovative biomedical enterprise with excellent independent R & D capability as the core driving force. It has comprehensive R & D and commercialization capabilities, focuses on the fields with huge unmet clinical needs such as tumors and autoimmune diseases, and develops the best or first-of-a-kind drugs with breakthrough potential in the global market.
The company has a founding team and management team with international innovation vision and profound industry insight. The founding team of the company has cooperated for many years, complementing each other professionally and cooperating tacitly to jointly promote the efficient and rapid development of the company. The co founders of the company are Dr. Jisong Cui and Dr. Shi Yigong. Dr. Jisong Cui once served as the general manager of BAONUO Technology (Beijing) Co., Ltd. and the head of Merck & Co.’s early development team. Dr. Shi Yigong is a well-known structural biologist. He is now an academician of the Chinese Academy of Sciences, a foreign academician of the American Academy of Arts and Sciences, a foreign academician of the National Academy of Sciences Foreign member of European Molecular Biology Organization (EMBO), founding president of West Lake University, Chair Professor of School of life sciences of Tsinghua University, etc. The main management team members of the company have the senior working experience of Pfizer Inc., GlaxoSmithKline PLC, Bristol Myers Squibb Company, Johnson & Johnson and other large multinational pharmaceutical companies, and inject foresight into the company in the R & D, production and commercialization of innovative drugs.
Under the leadership of the management team with rich experience in R & D, production and commercialization, the company has established an integrated biomedical platform, taking into account the needs of R & D quality and R & D speed, established a product pipeline with a high balance of innovation and risk and covering multiple hot targets with great market prospects, and is accelerating its growth into a biomedical leader in developing and providing innovative therapies for patients with tumors and autoimmune diseases all over the world. As of the signing date of the listing sponsor, one of the company’s main products, albutinib (enokai) ®） It has been approved by the State Food and Drug Administration in December 2020. Nine products are in phase I / II / III clinical trial stage and six products are in preclinical stage. The company is rapidly promoting the clinical trial and registration application of products under research in the global market dominated by China and the United States, so as to realize the candidate drugs in the product pipeline to benefit patients around the world as soon as possible.
The company’s product layout focuses on the field of tumor and autoimmune diseases with broad market space, and focuses on the construction of innovative therapies with synergistic effects. According to frost Sullivan’s analysis, the global tumor drug market will reach 150.3 billion US dollars in 2020 and is expected to grow to 482.5 billion US dollars in 2030; The global autoimmune disease drug market will reach 120.6 billion US dollars in 2020 and is expected to grow to 175.2 billion US dollars in 2030. In terms of hematoma, the company has hematoma treatment products with highly differentiated competitive advantages and synergistic effects, such as orbutinib (Btk inhibitor), icp-490 (crbn E3 ligase regulator) and tafasitamab (monoclonal antibody targeting CD19)
